Allegro DVT and Beamr Announce the World’s First Content-Adaptive Silicon IP Video Encoder
23.9.2021 16:35:00 EEST | Business Wire | Press release
Allegro DVT, the leading provider of video processing silicon IPs, and Beamr, the leading developer of content-adaptive video encoding technologies, today announced an integrated solution that combines Beamr’s CABR silicon IP with Allegro’s video encoding IP to create the world’s first content-adaptive silicon IP encoder. Using the integrated solution, ASIC vendors can now create high-performance, low latency video encoding chips that significantly reduce video bitrate without compromising quality.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923005015/en/
(Photo: Allegro DVT)
Allegro DVT’s E2xx family of silicon proven IPs is a highly optimized video encoding solution targeted at ASIC implementations in a wide range of process node technologies down to 3nm. It provides support for mainstream image and video formats including JPEG, H.264, HEVC, VP9 and AV1, at up to 8K resolutions.
Beamr’s patented, Emmy® award-winning CABR engine enables reducing the bitrate of video streams encoded by any standard video encoder, including the latest AV1 codec, by up to 50% without compromising perceptual quality. The reduced-bitrate streams remain fully standards-compliant, and can be decoded by any standard video decoder.
“For the past decade, Beamr’s CABR software solutions have enabled optimized video compression for our customers, resulting in an improved viewing experience, reduced network congestion, and lower TCO”, said Sharon Carmel, Founder & CEO of Beamr. “When developing our silicon IP implementation, we’ve found Allegro’s video encoders to be the perfect partner for integration, due to their superior video quality, high performance, and support for the latest video codecs. By integrating our CABR Silicon IP library with Allegro’s video encoders, we are now bringing the optimization benefits to ASIC providers, who can utilize them in all video applications from video surveillance and IoT to 8K live broadcasting, low latency cloud gaming and more.”
Nouar Hamze, Allegro DVT’s CEO commented: “The dramatic increase of video usage is forcing the industry to consider HW based video encoding solutions to control implementation complexity and cost. The integrated Allegro DVT E2xx/Beamr CABR solution provides our common customer base with the most advanced ASIC-ready option to further improve video compression efficiency. The combined solution is immediately available for evaluation through a bit-accurate software simulation model.”
About Beamr
https://beamr.com/
About Allegro DVT
http://www.allegrodvt.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005015/en/
Contact information
Nathalie Brault
marcom@allegrodvt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CAIRDAC Adds Operational Expertise to Its Board of Directors With the Appointment of Rinda Sama9.11.2026 14:44:00 EET | Press release
CAIRDAC, SA, a pre-revenue-stage medtech company developing ALPS™, a leadless, self-powered cardiac pacing system, today announced the appointment of Mr. Rinda Sama to its Board of Directors. His appointment adds deep manufacturing, quality and operational experience to the Board and follows the recent appointment of Raymond W. Cohen as Chairman. “Mr. Sama’s extensive experience in manufacturing, quality systems and operational scale-up for complex implantable devices will be extremely valuable to our Company as we prepare for clinical evaluation and the next stages of development,” said Edouard Fonck, Chief Executive Officer of CAIRDAC. Mr. Sama currently serves as CEO of Spiro Medical, a company focused on treating asthma employing a proprietary neuromodulation system. He previously served as Chief Operating Officer of publicly traded Axonics, Inc. where he was accountable for manufacturing and quality and the operational infrastructure that supported the company’s commercial growth.
Nominations Open for Sixth Edition of Aster Guardians Global Nursing Award 2027 Worth USD 250,000 Prize9.11.2026 14:35:00 EET | Press release
Aster DM Healthcare has announced the launch of the sixth edition of the Aster Guardians Global Nursing Award, inviting registered nurses worldwide to showcase their contributions to healthcare and compete for a prize of USD 250,000. The award recognises nurses whose work advances patient care, strengthens healthcare systems, drives innovation and transforms communities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109180902/en/ Aster Guardians Global Nursing Award - One nurse will win the trophy and the prize of USD 250,000 (Photo: AETOSWire) Open to registered nurses worldwide, the award recognises contributions across five areas: Patient Care, Nursing Education, Social and Community Service, Research and Innovation, and Nursing Leadership and Administration. Applicants can share their professional journeys through case-study questions, in multiple languages at www.asterguardians.com until December 31, 2026. The 2026
Datavault AI and Biochar Now Combine Insured Carbon Removal Credits with Patented Tokenization Technology9.11.2026 13:45:00 EET | Press release
Datavault AI Inc. (“Datavault” or the “Company”) (Nasdaq: DVLT), today announced a global strategic collaboration with Biochar Now to expand the distribution of verified, insured carbon removal credits through Datavault’s patented tokenization technology and global marketing and distribution capabilities. The partnership is designed to connect Biochar Now’s carbon removal credits with a broader network of buyers while strengthening transparency, traceability and accountability in the carbon markets. Under the agreement, Datavault AI will provide access to its carbon credit tokenization technology, including U.S. Patent No. 12,443,977 and related pending applications. It will also support worldwide demand generation, buyer development, marketing and distribution of eligible Biochar Now carbon credits, while also pursuing listings with existing and future partner exchange platforms. Biochar Now will pay Datavault AI for its technology and services; specific financial terms were not discl
NIQ to Present at 2026 J.P. Morgan Ultimate Services Investor Conference9.11.2026 13:45:00 EET | Press release
NielsenIQ (NYSE: NIQ) (the “Company”, or “NIQ”), a leading global consumer intelligence company, today announced that Jim Peck, Chairman and CEO, and Mike Burwell, CFO will participate in a fireside chat at the J.P. Morgan Ultimate Services Investor Conference on Tuesday, November 17, 2026 at 2:40 pm ET. A live webcast will be available on the NIQ investor relations website at https://investors.nielseniq.com. A replay will also be available on the Company's website following the conclusion of the presentation. About NielsenIQ NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior. Combining an unmatched global data footprint, granular consumer and retail measurement, and decades of AI modeling expertise, NIQ helps companies turn complex data into confident action. With operations in more than 90 countries covering approximately 82% of the world’s population and more than $7.4 trillion in consumer spend, N
Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression9.11.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the Company completed its submission of a New Drug Application (NDA) to the U.S. FDA for COMP360 psilocybin, its investigational synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). "People living with treatment-resistant depression have gone too long experiencing disproportionate suffering, despite years of trying available treatment options without meaningful relief. The completion of our NDA submission reflects years of perseverance and commitment by patients, families, advocates, researchers and healthcare providers who have worked alongside us toward the shared goal of bringing new treatment options to this community,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “Compass is leading the development of this new class of medicines with rigor and discipline, successfully
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom